Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Charles Williams / Flickr Creative Commons
The Food and Drug Administration gave the green light Thursday to Mavyret, a hepatitis C drug made by AbbVie. Mavyret's list price is $26,400 for an eight-week treatment, the most common, and $39,600 for 12 weeks, an AbbVie spokesperson told Axios.
Why it matters: AbbVie's latest hepatitis C drug is a lot cheaper than Harvoni, the dominant hepatitis C medication made by Gilead Sciences. Harvoni retails for about $63,000 for eight weeks, although Gilead gets only about half of that after rebates and discounts. Even still, the lower-cost Mavyret could force pharmacy benefit managers and health insurers to consider putting it on their preferred drug lists in addition to, or instead of, Gilead's drugs.